We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+10.92%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$657M
AUM Growth
-$6.71M
Cap. Flow
+$44.5M
Cap. Flow %
6.78%
Top 10 Hldgs %
66.42%
Holding
38
New
3
Increased
16
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$24.1M
2
ELVN icon
Enliven Therapeutics
ELVN
+$22.5M
3
VERA icon
Vera Therapeutics
VERA
+$21.8M
4
AKRO
Akero Therapeutics
AKRO
+$11.3M
5
BLU
BELLUS Health Inc.
BLU
+$9.9M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$29.7M
2
ACLX
Arcellx
ACLX
+$18.3M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$15.8M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$13.3M
5
ETNB
89bio
ETNB
+$9.65M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
1
Xenon Pharmaceuticals
XENE
$6.32B
$66M 10.05%
1,845,000
+185,889
+11% +$6.87M
VRDN icon
2
Viridian Therapeutics
VRDN
$2.13B
$55.7M 8.48%
2,189,659
+169,493
+8% +$5.43M
MRUS
3
DELISTED
Merus
MRUS
$54.3M 8.26%
2,950,000
+217,433
+8% +$3.79M
COGT icon
4
Cogent Biosciences
COGT
$6.79B
$51.5M 7.84%
4,772,421
+452,481
+10% +$5.79M
BLU
5
DELISTED
BELLUS Health Inc.
BLU
$47.4M 7.21%
6,579,359
+1,275,802
+24% +$9.9M
AMAM
6
DELISTED
Ambrx Biopharma Inc
AMAM
$42.8M 6.52%
+4,803,447
New +$24.1M
ELVN icon
7
Enliven Therapeutics
ELVN
$3.78B
$37.9M 5.77%
1,731,365
+1,107,666
+178% +$22.5M
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$30.2M 4.6%
790,000
+252,924
+47% +$11.3M
NUVL
9
DELISTED
Nuvalent
NUVL
$28M 4.27%
1,075,000
+161,379
+18% +$4.77M
IMVT icon
10
Immunovant
IMVT
$8.09B
$22.3M 3.4%
1,440,999
+290,494
+25% +$5.04M
VERA icon
11
Vera Therapeutics
VERA
$2.54B
$21.9M 3.34%
+2,824,029
New +$21.8M
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.84B
$18M 2.75%
853,884
+165,439
+24% +$4.12M
CLDX icon
13
Celldex Therapeutics
CLDX
$2.77B
$17.8M 2.72%
495,823
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$17.7M 2.69%
2,025,000
-3,713,500
-65% -$29.7M
CABA icon
15
Cabaletta Bio
CABA
$439M
$15.2M 2.31%
1,835,000
+824,641
+82% +$7.72M
KURA icon
16
Kura Oncology
KURA
$922M
$14.7M 2.24%
1,204,958
+105,551
+10% +$1.32M
ARWR icon
17
Arrowhead Research
ARWR
$12.1B
$14.6M 2.22%
575,000
+112,889
+24% +$3.55M
CELC icon
18
Celcuity
CELC
$4.03B
$14.3M 2.17%
1,390,772
+62,820
+5% +$688K
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$13.6M 2.08%
127,156
– –
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.2M 1.56%
1,325,000
– –
DAWN
21
DELISTED
Day One Biopharmaceuticals
DAWN
$9.89M 1.51%
739,661
– –
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$9.07M 1.38%
590,705
– –
ENTA icon
23
Enanta Pharmaceuticals
ENTA
$372M
$8.79M 1.34%
217,253
-6,241
-3% -$298K
ALLK
24
DELISTED
Allakos
ALLK
$8.46M 1.29%
1,900,000
+256,500
+16% +$1.64M
PCVX icon
25
Vaxcyte
PCVX
$7.89B
$7.5M 1.14%
200,000
+26,519
+15% +$1.12M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Commodore Capital held 38 positions worth $657M, down 1% from $664M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Commodore Capital deployed $44.5M of net new capital in Q1 2023, opening 3 new positions and adding to 16 existing holdings. Its largest new stake was Ambrx Biopharma Inc: 4,803,447 shares worth $42.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $29.7M trimmed.

  • Commodore Capital's largest Q1 2023 buy was Ambrx Biopharma Inc: 4,803,447 shares worth $42.8M.
  • Commodore Capital added most to Enliven Therapeutics in Q1 2023, an estimated $22.5M increase.
  • Commodore Capital's biggest Q1 2023 reduction was Cymabay Therapeutics, cutting an estimated $29.7M.
  • Commodore Capital fully exited Arcellx in Q1 2023, selling an estimated $18.3M.
  • Commodore Capital's ten largest holdings make up 66% of its $657M portfolio in Q1 2023.
  • Commodore Capital opened 3 new positions and closed 6 in Q1 2023.
  • Commodore Capital's portfolio value fell 1% quarter-over-quarter to $657M.

Based on Commodore Capital's 13F filing for Q1 2023, filed 15 May 2023.